FewerJobs.
All jobs

Senior Research Associate, Proteomics

Revolution Medicines - Redwood City, California, United States

Posted May 28, 2026

Benefits

Parental leave
Not verified
Non-birth-parent leave
Not verified
Family-building benefits
  • Fertility benefits: Not verified
  • Adoption assistance: Not verified
  • Surrogacy assistance: Not verified
Mental health support
Not verified
Relocation assistance
Not verified
Childcare support
Not verified
Learning budget
Not verified
Verification
Not verified checked Jun 7, 2026
Salary
$106K-$126K From the posting source checked Jun 20, 2026
401(k) match
Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)
$111,944 U.S. median for this role
Projected growth (BLS Employment Projections)
+13.7% - Much faster than average

4% above the BLS role benchmark for data and ml aggregate.

Matched to SOC 15-1252 - Data and ML aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function
Data From the posting source checked Jun 20, 2026
Seniority
Senior From the posting source checked Jun 20, 2026

Schedule

Shift type
Not verified
Weekend work
Not verified

Company

Equity
Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter
Not verified
Assessment
Not verified
Deadline
Not stated

Where they hire

State eligibility is not yet verified.

About this role

Senior Research Associate, Proteomics Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a motivated and detail-oriented individual to support and advance mass spectrometry-based proteomics workflows. This role is well-suited for a scientist with prior industry experience who is excited to apply and expand their expertise in proteomics within a drug discovery environment. This position will involve executing and optimizing laboratory workflows, maintaining high-quality data standards, and contributing to the development of new capabilities within the team. The ideal candidate will demonstrate strong technical proficiency, attention to detail, and the ability to work both independently and collaboratively. In this role, success will come from consistently delivering high-quality, reproducible data, maintaining well-documented experiments, and proactively identifying opportunities to improve workflows and efficiency. As a key member of the Proteomics group within our dynamic Chemical Biology team, you will: - Perform sample preparation for bottom-up proteomics workflows with high attention to detail and reproducibility.

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.

Apply at revmed.com

Apply link not verified; last-live date unavailable.

What verified means

Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.

Related jobs